Woodline Partners LP Akebia Therapeutics, Inc. Transaction History

Woodline Partners LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $1.61 Million - $6.54 Million	-2,231,966 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.26 - $3.34 $206,905 - $305,780	-91,551 Reduced 3.94%	2,231,966 $5.04 Million
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $5.17 Million - $8.54 Million	2,199,743 Added 1777.23%	2,323,517 $6.69 Million
Q2 2021 Aug 16, 2021	BUY	$2.83 - $4.2 $350,280 - $519,850	123,774 New	123,774 $469,000
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $6.96 Million - $12.1 Million	-2,382,522 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $6.83 Million - $11.6 Million	-3,076,414 Reduced 56.36%	2,382,522 $6.67 Million
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $11.5 Million - $63 Million	4,814,707 Added 747.36%	5,458,936 $13.7 Million
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $116,851 - $237,908	17,519 Added 2.8%	644,229 $8.75 Million
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $2.65 Million - $6.62 Million	-646,077 Reduced 50.76%	626,710 $4.75 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $4.02 Million - $8.57 Million	1,272,787 New	1,272,787 $8.04 Million

110

55.3M

554K

246K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $245M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.